Apnimed Stock

apnimed.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $208.02MM

Apnimed, founded in 2017, is a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, MA, the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Register for Details

For more details on financing and valuation for Apnimed, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Apnimed.

Register Today

Apnimed investors also invested in these private companies

Team

Management Team

Dennis Molnar
Chief Operating Officer
Luigi Montemurro MD
Co-Founder & Chief Scientific Officer
Barry Wohl
Chief Business Officer
Rob Rode
Chief Commercial Officer
Andrew Wellman MD
Co-Founder & Advisor
Ron Farkas Ph.D
Chief Medical Officer
Lawrence Miller MD
Founder & Chief Executive Officer
Michael Rogers
Chief Financial Officer

Board Members

Chris Dimitropoulos
Alpha Wave Global
Isaac Cheng MD
Morningside Group
Stefan Larson Ph.D
Sectoral Asset Management

Other companies like Apnimed in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)
Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced today that it has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million.
Updated on: Sep 21, 2023